Day One of the 2026 National Reimbursement Drug List Negotiations: Representatives from Multiple Companies Display Visible Joy as Traditional Chinese Medicine and Chronic Disease Drugs Take Center Stage

The annual national medical insurance catalog negotiations have once again entered the stage of on-site bargaining.

cls.cnSep 5 18:02

Shanghai Junshi Biosciences Sets Date for 2026 Interim Results Investor Briefing

TipRanksSep 4 21:11

UBS Group: Chinese biotech firms’ H1 sales largely exceeded expectations; global R&D catalysts in H2 will be key; BeiGene is the top pick.

UBS Group released a report stating that market expectations for the Chinese biotechnology sector during the first-half earnings season were initially conservative, primarily due to concerns over tighter regulations on domestic drug marketing activities and anti-corruption campaigns in public hospitals. However, Chinese biotech companies focused on innovative drugs were only mildly affected. Among the 12 biotech companies covered by UBS (11 of which have reached the commercialization stage), eight reported sales that exceeded expectations, and none cited regulatory issues as a major obstacle to commercialization. UBS noted that total product sales for these 11 companies grew by 34% year-on-year in the first half of the year. BeiGene (ONC.US) led the pack with $3.2 billion in product sales, a 31% year-on-year increase.

AASTOCKSSep 4 13:37

UBS Remains a Buy on Shanghai Junshi Biosciences Co., Ltd. Class H (1877)

TipRanksSep 3 21:05

Zhitong AH Statistics | September 2

AH Statistics | September 2

Zhitong FinanceSep 2 16:15

Junshi Biosciences (01877.HK): Shanghai Tanying plans to reduce its shareholding by no more than 2%

Gelonghui, August 31 | Junshi Biosciences (01877.HK) announced that Shanghai Tanying Investment Partnership (Limited Partnership) (hereinafter referred to as "Shanghai Tanying"), which maintains a long-term positive outlook on the company's development, plans to reduce its shareholding by no more than 20.5338 million shares, representing no more than 2% of the company's total share capital, through centralized bidding and block trades due to fund maturity and liquidity arrangements. As of the date of this announcement, Shanghai Tanying holds 38.9256 million A-shares of the company, accounting for 3.7914% of the total share capital. The aforementioned shares are

Gelonghui FinanceAug 31 08:11